India, June 30 -- Today's top gainers in the biotech space include Cuprina, which recently received FDA clearance for its maggot-based wound treatment; ABIVAX, following encouraging results from an ulcerative colitis study; ProMIS, which has a key catalyst to watch this quarter; and surgical robotic company SS Innovations, among others.
Read on.
Cuprina On the Move
Cuprina Holdings (Cayman) Limited (CUPR) was up over 47% on Tuesday, on no specific news.
Last month, the FDA gave clearance to MEDIFLY Maggots, the company's medical-grade Lucilia cuprina larvae used in maggot debridement therapy (MDT).
MEDIFLY Maggots is cleared for the debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, neuropathic ...